Advertisement
News
Advertisement

FDA approves Codman implantable infusion pump for treatment of movement disorders

Wed, 08/08/2012 - 6:41pm
Mass Device

Johnson & Johnson neurological devices subsidiary Codman & Shurtleff enters the neuromodulation market with FDA approval for the Medstream programmable infusion system for treatment of movement disorders.

Medstream infusion pump

The FDA granted PMA supplemental approval to Codman & Shurtleff for the Medstream programmable infusion device, an implantable infusion pump and catheter used in treatment of movement disorders.

The Medstream system delivers continuous doses of an anti-spasm drug directly to he spinal canal to relieve spasticity, a disorder affecting more than 12 million people worldwide, which is often caused by stroke, cerebral palsy, multiple sclerosis or spinal cord injury, according to the company.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading